Shiven Patel, MD
Hematology & Oncology · Salt Lake City, UTNPI 1023276490
Payments from drug & device makers
Across 399 payments — averaging $7192.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.9M
- AstraZeneca$333K
- Boehringer Ingelheim$137K
- Merck$129K
- Boehringer Ingelheim Pharma GmbH & Co.kg$94K
- Astrazeneca UK Limited$71K
- plus $223K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 85 | $1,882,810 |
| AstraZeneca | 55 | $333,245 |
| Boehringer Ingelheim | 11 | $136,978 |
| Merck | 40 | $128,521 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 29 | $94,151 |
| Astrazeneca UK Limited | 2 | $70,721 |
| AbbVie | 4 | $67,306 |
| Regeneron Healthcare Solutions, Inc. | 65 | $67,142 |
| E.r. Squibb & Sons, L.L.C. | 34 | $38,762 |
| Amgen | 38 | $22,890 |
| Blueprint Medicines Corporation | 2 | $4,750 |
| Regeneron | 2 | $3,734 |
| Sanofi | 2 | $2,933 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,920 |
| Jazz Pharmaceuticals Inc. | 1 | $2,450 |
| Pfizer | 4 | $2,436 |
| Boehringer Ingelheim International GmbH | 1 | $1,443 |
| Lantheus Medical Imaging, Inc. | 1 | $998 |
| Beigene, Ltd. | 1 | $982 |
| Novartis | 4 | $754 |
| Dr.reddy's Laboratories,inc. | 1 | $750 |
| Cipla USA Inc. | 1 | $750 |
| Daiichi Sankyo Inc. | 2 | $750 |
| Immunocore Limited | 1 | $500 |
| Tersera Therapeutics LLC | 1 | $386 |
| Nuvation Bio Inc. | 2 | $286 |
| Sobi, Inc | 1 | $200 |
| Incyte Corporation | 2 | $185 |
| Johnson & Johnson | 2 | $111 |
| GSK | 2 | $35 |
| Tempus AI, Inc | 1 | $28 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,869,916 in reported general payments places this provider in the 90th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Neeraj AgarwalSalt Lake City$32.4M
- Douglas SborovSalt Lake City$7.8M
- Tsewang TashiSalt Lake City$6.7M
- Benjamin MaughanSalt Lake City$5.6M
- Daanish HodaSalt Lake City$2.9M
- Vaia FlorouSalt Lake City$2.3M
- Theresa WernerSalt Lake City$1.9M
- Heloisa SoaresSalt Lake City$1.7M
- Sunil SharmaSalt Lake City$1.5M
- Brian McCluneSalt Lake City$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.